Protocol Ledger

NCT04645966 · Phase II · TERMINATED

A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

Interventional Phase II clinical trial protocol NCT04645966 sponsored by Pfizer in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-11-26 Enrollment: 326 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04645966
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)326 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04645966
Protocol FieldVerified Registry Value
NCT IdentifierNCT04645966
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment326 participants (ACTUAL)
Registered Start Date2020-11-26
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04645966
Hospital Research SiteLocationSite Profile
Hospital Universitari Germans Trias i PujolBadalona, SpainOpen Hospital Dossier ->
Hospital General Universitario Gregorio MarañónMadrid, SpainOpen Hospital Dossier ->
Hospital Universitario 12 de OctubreMadrid, SpainOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI